查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1291420

抗高脂血症药物市场：2023-2028年全球行业趋势、份额、规模、增长、机会和预测

Antihyperlipidemic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 144 Pages | 商品交期: 2-3个工作天内

价格

市场概况：

2022年，全球抗高脂血症药物市场规模达到120亿美元。展望未来，IMARC集团预计，到2028年，市场规模将达到160亿美元，在2023-2028年期间呈现4.6%的增长率（CAGR）。

抗高血脂药物有助于降低血液中的胆固醇和各种脂质的血清水平。它们可以与不同的药物一起服用，以控制高胆固醇和减少某些医疗状况的风险。目前，它们的不同类别在全世界范围内都有，可以根据病人的胆固醇情况、潜在疾病和其他因素给予治疗。一些常用的抗高脂血症药物包括他汀类、抗高脂血症组合、胆汁酸螯合剂、胆固醇吸收抑制剂、纤维酸衍生物和PCSK9抑制剂。

抗高脂血症药物的市场趋势：

由于久坐的生活方式、尼古丁成瘾和大量食用高脂肪食物，高脂血症的发病率越来越高，这是催化抗高脂血症药物需求的关键因素之一。此外，高脂血症增加了患冠状动脉疾病（CAD）的风险，这是全世界成年人最常见的死亡原因。因此，对这些药物的需求上升，以减少高水平的低密度脂蛋白（LDL）胆固醇和甘油三酯，同时增加高密度脂蛋白（HDL）胆固醇的低水平。除此以外，它们还被用于治疗儿童的高胆固醇水平和各种血脂紊乱。此外，儿科人群中遗传性和获得性脂质和脂蛋白代谢紊乱的数量激增，对抗高脂血症药物的需求产生了积极影响，以减少住院率和过早死亡。此外，新的和先进的药物的批准正在为市场创造一个有利的前景。除此之外，世界各地的药物化学家正在设计、合成和评估这些药物的各种新分子，预计这将促进市场的增长。

本报告中回答的关键问题：

  • 2022年全球抗高脂血症药物市场的规模是多少？
  • 2023-2028年全球抗高脂血症药物市场的预期增长率是多少？
  • 推动全球抗高脂血症药物市场的关键因素是什么？
  • COVID-19对全球抗高脂血症药物市场的影响是什么？
  • 全球抗高脂血症药物市场基于药物类别的细分情况是什么？
  • 基于分销渠道的全球抗高脂血症药物市场的细分情况如何？
  • 全球抗高脂血症药物市场的主要地区有哪些？
  • 谁是全球抗高脂血症药物市场的主要参与者/公司？

目录

第一章：前言

第二章：范围和方法

  • 研究的目标
  • 利益相关者
  • 数据来源
    • 主要来源
    • 二级来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

  • 概述
  • 主要行业趋势

第五章：全球抗高脂血症药物市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：按药物类别分類的市场

  • 他汀类药物
    • 市场趋势
    • 市场预测
  • 胆汁酸螯合剂
    • 市场趋势
    • 市场预测
  • 胆固醇吸收抑制剂
    • 市场趋势
    • 市场预测
  • 纤维酸衍生物
    • 市场趋势
    • 市场预测
  • PCSK9抑制剂
    • 市场趋势
    • 市场预测
  • 组合药物
    • 市场趋势
    • 市场预测
  • 其他
    • 市场趋势
    • 市场预测

第7章 ：按给药途径分類的市场

  • 口服
    • 市场趋势
    • 市场预测
  • 静脉注射
    • 市场趋势
    • 市场预测

第8章：按分销渠道分類的市场

  • 医院药房
    • 市场趋势
    • 市场预测
  • 零售店
    • 市场趋势
    • 市场预测
  • 网上零售商
    • 市场趋势
    • 市场预测

第九章：按地区分類的市场

  • 北美洲
    • 美国
      • 市场趋势
      • 市场预测
    • 加拿大
      • 市场趋势
      • 市场预测
  • 亚太地区
    • 中国
      • 市场趋势
      • 市场预测
    • 日本
      • 市场趋势
      • 市场预测
    • 印度
      • 市场趋势
      • 市场预测
    • 韩国
      • 市场趋势
      • 市场预测
    • 澳大利亚
      • 市场趋势
      • 市场预测
    • 印尼
      • 市场趋势
      • 市场预测
    • 其他国家
      • 市场趋势
      • 市场预测
  • 欧洲
    • 德国
      • 市场趋势
      • 市场预测
    • 法国
      • 市场趋势
      • 市场预测
    • 英国
      • 市场趋势
      • 市场预测
    • 意大利
      • 市场趋势
      • 市场预测
    • 西班牙
      • 市场趋势
      • 市场预测
    • 俄罗斯
      • 市场趋势
      • 市场预测
    • 其他国家
      • 市场趋势
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场趋势
      • 市场预测
    • 墨西哥
      • 市场趋势
      • 市场预测
    • 其他国家
      • 市场趋势
      • 市场预测
  • 中东和非洲
    • 市场趋势
    • 按国家分類的市场
    • 市场预测

第十章：SWOT分析

  • 概述
  • 优势
  • 劣势
  • 机会
  • 威胁

第十一章 ：价值链分析

第十二章 ：波特斯五力分析

  • 概述
  • 买方的讨价还价能力
  • 供应商的讨价还价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第十三章 ：价格分析

第十四章：竞争格局

  • 市场结构
  • 主要参与者
  • 主要参与者的概况
    • Amgen Inc.
    • AstraZeneca plc
    • Daiichi Sankyo Company Limited
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A
Product Code: SR112023A5622

Market Overview:

The global antihyperlipidemic drugs market size reached US$ 12.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 16.0 Billion by 2028, exhibiting a growth rate (CAGR) of 4.6% during 2023-2028.

Antihyperlipidemic drugs help lower serum levels of cholesterol and various lipids in the blood. They can be taken with different medications to control high cholesterol and reduce the risk of certain medical conditions. At present, their different classes are available worldwide, which can be given based on the patient's cholesterol profile, underlying disease, and other factors. Some of the commonly available antihyperlipidemic drugs include statins, antihyperlipidemic combinations, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and PCSK9 inhibitors.

Antihyperlipidemic Drugs Market Trends:

The growing prevalence of hyperlipidemia on account of sedentary lifestyles, nicotine addiction, and high consumption of fatty foods represents one of the key factors catalyzing the demand for antihyperlipidemic drugs. Moreover, hyperlipidemia increases the risk of developing coronary artery disease (CAD), which is the most common cause of death among adults worldwide. As a result, there is a rise in the need for these drugs to reduce the high levels of low-density lipoprotein (LDL) cholesterol and triglycerides while increasing the low levels of high-density lipoprotein (HDL) cholesterol. Apart from this, they are used to treat children with high cholesterol levels and various lipid disorders. In addition, a surge in the number of genetic and acquired disorders of lipid and lipoprotein metabolism among the pediatric population is positively influencing the need for antihyperlipidemic drugs to reduce the rates of hospitalization and premature deaths. Furthermore, the approval of new and advanced drugs is creating a favorable outlook for the market. Besides this, medicinal chemists around the world are designing, synthesizing, and evaluating a variety of new molecules for these drugs, which is anticipated to contribute to the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antihyperlipidemic drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug class, route of administration and distribution channel.

Breakup by Drug Class:

  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • Fibric Acid Derivatives
  • PCSK9 Inhibitors
  • Combination
  • Others

Breakup by Route of Administration:

  • Oral
  • Intravenous

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Stores
  • Online Retailers

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Sanofi S.A.

Key Questions Answered in This Report:

  • What was the size of the global antihyperlipidemic drugs market in 2022?
  • What is the expected growth rate of the global antihyperlipidemic drugs market during 2023-2028?
  • What are the key factors driving the global antihyperlipidemic drugs market?
  • What has been the impact of COVID-19 on the global antihyperlipidemic drugs market?
  • What is the breakup of the global antihyperlipidemic drugs market based on the drug class?
  • What is the breakup of the global antihyperlipidemic drugs market based on the distribution channel?
  • What are the key regions in the global antihyperlipidemic drugs market?
  • Who are the key players/companies in the global antihyperlipidemic drugs market?

Table of Contents

1   Preface

2   Scope and Methodology

  • 2.1  Objectives of the Study
  • 2.2  Stakeholders
  • 2.3  Data Sources
    • 2.3.1  Primary Sources
    • 2.3.2  Secondary Sources
  • 2.4  Market Estimation
    • 2.4.1  Bottom-Up Approach
    • 2.4.2  Top-Down Approach
  • 2.5  Forecasting Methodology

3   Executive Summary

4   Introduction

  • 4.1  Overview
  • 4.2  Key Industry Trends

5   Global Antihyperlipidemic Drugs Market

  • 5.1  Market Overview
  • 5.2  Market Performance
  • 5.3  Impact of COVID-19
  • 5.4  Market Forecast

6   Market Breakup by Drug Class

  • 6.1  Statins
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2  Bile Acid Sequestrants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3  Cholesterol Absorption Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4  Fibric Acid Derivatives
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5  PCSK9 Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6  Combination
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7  Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7   Market Breakup by Route of Administration

  • 7.1  Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2  Intravenous
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8   Market Breakup by Distribution Channel

  • 8.1  Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2  Retail Stores
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3  Online Retailers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9   Market Breakup by Region

  • 9.1  North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2  Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3  Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4  Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5  Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10  SWOT Analysis

  • 10.1  Overview
  • 10.2  Strengths
  • 10.3  Weaknesses
  • 10.4  Opportunities
  • 10.5  Threats

11  Value Chain Analysis

12  Porters Five Forces Analysis

  • 12.1  Overview
  • 12.2  Bargaining Power of Buyers
  • 12.3  Bargaining Power of Suppliers
  • 12.4  Degree of Competition
  • 12.5  Threat of New Entrants
  • 12.6  Threat of Substitutes

13  Price Analysis

14  Competitive Landscape

  • 14.1  Market Structure
  • 14.2  Key Players
  • 14.3  Profiles of Key Players
    • 14.3.1  Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2  AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3  Daiichi Sankyo Company Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4  Merck & Co. Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5  Novartis AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6  Pfizer Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7  Sanofi S.A
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials

List of Figures

  • Figure 1: Global: Antihyperlipidemic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Antihyperlipidemic Drugs Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Antihyperlipidemic Drugs Market: Breakup by Drug Class (in %), 2022
  • Figure 5: Global: Antihyperlipidemic Drugs Market: Breakup by Route of Administration (in %), 2022
  • Figure 6: Global: Antihyperlipidemic Drugs Market: Breakup by Distribution Channel (in %), 2022
  • Figure 7: Global: Antihyperlipidemic Drugs Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Antihyperlipidemic Drugs (Statins) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Antihyperlipidemic Drugs (Statins) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Antihyperlipidemic Drugs (Combination) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Antihyperlipidemic Drugs (Combination) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Antihyperlipidemic Drugs (Oral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Antihyperlipidemic Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Antihyperlipidemic Drugs (Intravenous) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Antihyperlipidemic Drugs (Intravenous) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Antihyperlipidemic Drugs (Retail Stores) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Antihyperlipidemic Drugs (Retail Stores) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Antihyperlipidemic Drugs (Online Retailers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Antihyperlipidemic Drugs (Online Retailers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: North America: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: North America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: United States: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: United States: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Canada: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Canada: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Asia-Pacific: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Asia-Pacific: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: China: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: China: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Japan: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Japan: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: India: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: India: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: South Korea: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: South Korea: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Australia: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Australia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Indonesia: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Indonesia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Europe: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Europe: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Germany: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Germany: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: France: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: France: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: United Kingdom: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: United Kingdom: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Italy: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Italy: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Spain: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Spain: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Russia: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Russia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Latin America: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Latin America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Brazil: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Brazil: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Mexico: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Mexico: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Middle East and Africa: Antihyperlipidemic Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Middle East and Africa: Antihyperlipidemic Drugs Market: Breakup by Country (in %), 2022
  • Figure 80: Middle East and Africa: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 81: Global: Antihyperlipidemic Drugs Industry: SWOT Analysis
  • Figure 82: Global: Antihyperlipidemic Drugs Industry: Value Chain Analysis
  • Figure 83: Global: Antihyperlipidemic Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antihyperlipidemic Drugs Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
  • Table 3: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2023-2028
  • Table 4: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 5: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Antihyperlipidemic Drugs Market: Competitive Structure
  • Table 7: Global: Antihyperlipidemic Drugs Market: Key Players